CAPR - NASDAQ

Capricor Therapeutics, Inc.

CAPR·NASDAQ

$27.64

+1.1%

HealthcareBiotechnology

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.26B

EPS-2.2600

P/E Ratio-12.23

Earnings Date08/11/2026

355.95M

Assets

109%

3Y+611.0%

5Y+928.0%

10Y+1799.0%

50.16M

Total Liabilities

100%

3Y+31.0%

5Y+681.0%

10Y+120.0%

305.79M

Total Equity

110%

3Y+2495.0%

5Y+984.0%

10Y-7739.0%

Capricor Therapeutics, Inc. Funding & Solvency Profile

CAPR · NASDAQ

Current Assets

Cash & Cash Equivalents287.85M

Net Receivables59.17K

Inventory0.00

Other Current Assets0.00

Total Current Assets323 M

Non-Current Assets

Property, Plant & Equipment18.31M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets14.70M

Total Non-Current Assets33 M

Total Assets

355.95M

Financial Health Analysis

Current Ratio

9.01x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.16x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

287 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

91% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Capricor Therapeutics, Inc. Balance Sheet

CAPR • NASDAQ

Capricor Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	287.8M	11.3M	14.7M	9.6M	34.9M	32.7M	3.9M	4.3M	6.1M	3.2M	5.6M	8M	1.7M	170.1K	1M	3.4M	3.2M	5.5M	16.2M	0.0
Short-Term Investments	30.3M	140.2M	24.8M	31.8M	0.0	0.0	6M	3M	8M	13M	8M	0.0	326.5K	4.2M	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	318.1M	151.5M	39.5M	41.4M	34.9M	32.7M	9.9M	7.3M	14.1M	16.2M	13.6M	8M	2.1M	4.4M	1M	3.4M	3.2M	5.5M	16.2M	0.0
Net Receivables	59.2K	10.4M	10.4M	547.6K	391.8K	56K	88K	204.9K	344.6K	223.3K	211.9K	360.2K	0.0	792.4K	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	59.2K	10.4M	10.4M	547.6K	391.8K	56K	0.0	0.0	344.6K	223.3K	211.9K	360.2K	0.0	767.2K	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	88K	204.9K	0.0	0.0	0.0	0.0	0.0	767.2K	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	4.8M	1.5M	995.8K	0.0	1.2M	1M	571.4K	724.2K	501.2K	342.9K	210.6K	235.5K	223K	38K	271.3K	219.1K	257.7K	544.8K	526.3K	0.0
Other Current Assets	0.0	0.0	0.0	919.9K	0.0	-56K	0.0	285.8K	742K	1.3M	0.0	3M	1.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	322.9M	163.4M	50.9M	42.9M	36.4M	33.7M	10.5M	8.5M	15.7M	18.1M	14M	11.6M	3.7M	5.2M	1.3M	3.6M	3.4M	6M	16.8M	0.0
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	18.3M	6.9M	7.6M	6.9M	4.6M	850.8K	442.8K	574.2K	372.1K	435.3K	318.6K	229.5K	74.2K	33.9K	9.7K	16.8K	27.5K	73.7K	62.8K	0.0
Intangible Assets	0.0	0.0	0.0	0.0	0.0	2.2K	88K	204.9K	93K	142.3K	1.7M	1.7M	1.8M	178.3K	0.0	0.0	106.8K	209.5K	252.7K	0.0
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	2.2K	6.5K	49.8K	93K	142.3K	1.7M	1.7M	1.8M	178.3K	0.0	0.0	106.8K	209.5K	252.7K	0.0
Other Non-Current Assets	14.7M	221.7K	268.2K	268.2K	275.7K	88.7K	119.6K	151.8K	96K	61.4K	70.1K	55.3K	25.7K	18.1K	51.9K	51.9K	51.9K	106.6K	14K	0.0
Total Non-Current Assets	33M	7.1M	7.9M	7.2M	4.9M	941.7K	568.9K	775.8K	561.1K	639K	2.1M	2M	1.9M	230.3K	61.7K	68.7K	186.3K	389.8K	329.6K	0.0
Total Assets	355.9M	170.5M	58.7M	50.1M	41.3M	34.6M	11.1M	9.2M	16.3M	18.7M	16.1M	13.6M	5.5M	5.4M	1.4M	3.7M	3.6M	6.4M	17.1M	0.0
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.7M	8.2M	6.2M	4.9M	0.0	2.7M	898K	1.3M	1.7M	3.5M	2.9M	2.1M	2.1M	504.3K	476.7K	416.8K	234.8K	745.6K	658.8K	9.1K
Accounts Payable	1.7M	8.2M	6.2M	4.8M	0.0	2.7M	898K	1.3M	1.7M	3M	2.5M	1.7M	1.6M	264.7K	437.8K	332.4K	150.6K	745.6K	658.8K	9.1K
Other Payables	0.0	0.0	0.0	89.2K	0.0	0.0	0.0	0.0	0.0	489.2K	352.3K	433.7K	424K	239.6K	38.9K	84.4K	84.2K	0.0	0.0	0.0
Accrued Expenses	15.6M	10K	10K	0.0	0.0	9K	0.0	0.0	0.0	0.0	0.0	0.0	122.4K	24.9K	64.7K	652.3K	402.8K	586.3K	915.4K	0.0
Short Term Debt	6.4M	0.0	0.0	0.0	0.0	246.7K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	124.8K
Capital Lease Obligations (Current)	202.4K	834.8K	749.1K	682K	417.6K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	12M	0.0	0.0	18M	0.0	0.0	0.0	0.0	0.0	1.4M	3.6M	4.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	0.0	12M	24.3M	0.0	3.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-122.4K	0.0	0.0	0.0	0.0	0.0	315.2K	950.0
Total Current Liabilities	35.8M	21M	31.3M	23.6M	4.1M	3M	898K	1.3M	1.7M	4.9M	6.5M	6.3M	2.1M	529.2K	541.4K	1.1M	637.6K	1.3M	1.9M	134.8K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	71.5K	0.0	0.0	0.0	13.9M	9.2M	9.2M	4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	9.5M	0.0	0.0	0.0	0.0	0.0	0.0	911.5K	4.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	3.4M	3.4M	3.4M	3.4M	3.4M	3.4M	3.4M	3.4M	3.9M	505.4K	258.6K	58.1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	14.3M	4M	4.9M	14.7M	5.8M	3.4M	3.4M	3.4M	3.4M	17.9M	10.6M	13.6M	4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	14.5M	1.5M	2.2M	2.6M	2.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	50.2M	25M	36.1M	38.3M	10M	6.4M	4.3M	4.6M	5M	22.8M	17.1M	19.9M	6.1M	529.2K	541.4K	1.1M	637.6K	1.3M	1.9M	134.8K
SHAREHOLDERS' EQUITY
Common Stock	57.4K	45.6K	31.1K	25.2K	24.2K	20.6K	5.2K	3.1K	26.3K	21.4K	16.3K	11.7K	11.7K	10.4K	39.7K	34.6K	27.1K	24.2K	24.1K	7.6K
Additional Paid-In Capital	610.3M	344.2M	181.7M	148.7M	139.4M	116.2M	81.2M	71.3M	62.7M	50M	34.1M	16.1M	15.6M	12.1M	45.6M	42.5M	36.9M	31.1M	28.1M	47.2K
Retained Earnings	-304.9M	-199.8M	-159.4M	-137.1M	-108.1M	-88M	-74.4M	-66.7M	-51.5M	-54M	-35.2M	-22.3M	-16.1M	-7.2M	-44.8M	-39.9M	-33.9M	-26M	-12.9M	-189.6K
Accumulated Other Comprehensive Income/Loss	283.2K	1M	235.8K	105.2K	0.0	0.0	-757.0	12.4K	11.6K	3.5K	9.4K	0.0	-980.0	-21.8K	0.0	0.0	0.0	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.2K	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	305.8M	145.5M	22.6M	11.8M	31.4M	28.2M	6.8M	4.6M	11.2M	-4M	-1M	-6.2M	-534.9K	4.9M	830.7K	2.6M	3M	5.1M	15.2M	-134.8K
Total Equity	305.8M	145.5M	22.6M	11.8M	31.4M	28.2M	6.8M	4.6M	11.2M	-4M	-1M	-6.2M	-534.9K	4.9M	830.7K	2.6M	3M	5.1M	15.2M	-134.8K
SUMMARY
Total Liabilities & Equity	355.9M	170.5M	58.7M	50.1M	41.3M	34.6M	11.1M	9.2M	16.3M	18.7M	16.1M	13.6M	5.5M	5.4M	1.4M	3.7M	3.6M	6.4M	17.1M	0.0
Total Investments	30.3M	140.2M	24.8M	31.8M	0.0	0.0	6M	3M	8M	13M	8M	0.0	326.5K	4.2M	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	20.9M	1.5M	2.2M	2.6M	2.9M	318.2K	0.0	0.0	0.0	13.9M	9.2M	9.2M	4M	0.0	0.0	0.0	0.0	0.0	0.0	124.8K
Net Debt	-266.9M	-9.8M	-12.5M	-7M	-32M	-32.3M	-3.9M	-4.3M	-6.1M	10.7M	3.6M	1.1M	2.2M	-170.1K	-1M	-3.4M	-3.2M	-5.5M	-16.2M	124.8K
Shares Outstanding	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975	45,716,975

SEC Filings

CAPR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 10, 2026	June 04, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 17, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 10, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 05, 2025	December 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 03, 2025	December 03, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 03, 2025	December 03, 2025	2025	View Filing

Showing 1 to 10 of 348 filings

Related Guides

Blog Categories

Continue your CAPR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.